vs
Apellis Pharmaceuticals, Inc.（APLS）与Sprout Social, Inc.（SPT）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是Sprout Social, Inc.的1.7倍（$199.9M vs $120.9M），Sprout Social, Inc.同比增速更快（12.9% vs -5.9%），Sprout Social, Inc.自由现金流更多（$9.9M vs $-14.3M），过去两年Sprout Social, Inc.的营收复合增速更高（11.8% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Sprout Social, Inc.是一家提供社交媒体管理平台服务的科技企业，由贾斯汀·霍华德等四位创始人在2010年成立，总部位于美国芝加哥，目前是一家上市企业。其推出的平台能够帮助企业统一管理多渠道社媒账号，开展营销互动与数据分析工作。
APLS vs SPT — 直观对比
营收规模更大
APLS
是对方的1.7倍
$120.9M
营收增速更快
SPT
高出18.8%
-5.9%
自由现金流更多
SPT
多$24.2M
$-14.3M
两年增速更快
SPT
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $120.9M |
| 净利润 | $-59.0M | — |
| 毛利率 | — | 77.6% |
| 营业利润率 | -25.6% | -9.0% |
| 净利率 | -29.5% | — |
| 营收同比 | -5.9% | 12.9% |
| 净利润同比 | -62.2% | — |
| 每股收益（稀释后） | $-0.40 | $-0.18 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSSPT
| Q4 25 | $199.9M | $120.9M | ||
| Q3 25 | $458.6M | $115.6M | ||
| Q2 25 | $178.5M | $111.8M | ||
| Q1 25 | $166.8M | $109.3M | ||
| Q4 24 | $212.5M | $107.1M | ||
| Q3 24 | $196.8M | $102.6M | ||
| Q2 24 | $199.7M | $99.4M | ||
| Q1 24 | $172.3M | $96.8M |
净利润APLSSPT
| Q4 25 | $-59.0M | — | ||
| Q3 25 | $215.7M | $-9.4M | ||
| Q2 25 | $-42.2M | $-12.0M | ||
| Q1 25 | $-92.2M | $-11.2M | ||
| Q4 24 | $-36.4M | — | ||
| Q3 24 | $-57.4M | $-17.1M | ||
| Q2 24 | $-37.7M | $-16.9M | ||
| Q1 24 | $-66.4M | $-13.6M |
毛利率APLSSPT
| Q4 25 | — | 77.6% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 77.7% | ||
| Q1 25 | — | 77.3% | ||
| Q4 24 | — | 78.1% | ||
| Q3 24 | — | 77.4% | ||
| Q2 24 | — | 77.5% | ||
| Q1 24 | — | 76.8% |
营业利润率APLSSPT
| Q4 25 | -25.6% | -9.0% | ||
| Q3 25 | 48.7% | -7.9% | ||
| Q2 25 | -18.6% | -11.0% | ||
| Q1 25 | -50.0% | -10.2% | ||
| Q4 24 | -12.3% | -12.8% | ||
| Q3 24 | -24.0% | -16.4% | ||
| Q2 24 | -14.7% | -16.6% | ||
| Q1 24 | -36.0% | -13.7% |
净利率APLSSPT
| Q4 25 | -29.5% | — | ||
| Q3 25 | 47.0% | -8.1% | ||
| Q2 25 | -23.6% | -10.7% | ||
| Q1 25 | -55.3% | -10.3% | ||
| Q4 24 | -17.1% | — | ||
| Q3 24 | -29.2% | -16.6% | ||
| Q2 24 | -18.9% | -17.0% | ||
| Q1 24 | -38.5% | -14.0% |
每股收益（稀释后）APLSSPT
| Q4 25 | $-0.40 | $-0.18 | ||
| Q3 25 | $1.67 | $-0.16 | ||
| Q2 25 | $-0.33 | $-0.21 | ||
| Q1 25 | $-0.74 | $-0.19 | ||
| Q4 24 | $-0.30 | $-0.25 | ||
| Q3 24 | $-0.46 | $-0.30 | ||
| Q2 24 | $-0.30 | $-0.30 | ||
| Q1 24 | $-0.54 | $-0.24 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $95.3M |
| 总债务越低越好 | — | $40.0M |
| 股东权益账面价值 | $370.1M | $203.4M |
| 总资产 | $1.1B | $523.1M |
| 负债/权益比越低杠杆越低 | — | 0.20× |
8季度趋势，按日历期对齐
现金及短期投资APLSSPT
| Q4 25 | $466.2M | $95.3M | ||
| Q3 25 | $479.2M | $90.6M | ||
| Q2 25 | $370.0M | $101.5M | ||
| Q1 25 | $358.4M | $100.9M | ||
| Q4 24 | $411.3M | $86.4M | ||
| Q3 24 | $396.9M | $82.9M | ||
| Q2 24 | $360.1M | $80.9M | ||
| Q1 24 | $325.9M | $69.2M |
总债务APLSSPT
| Q4 25 | — | $40.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $25.0M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSSPT
| Q4 25 | $370.1M | $203.4M | ||
| Q3 25 | $401.2M | $194.1M | ||
| Q2 25 | $156.3M | $184.6M | ||
| Q1 25 | $164.2M | $175.3M | ||
| Q4 24 | $228.5M | $166.6M | ||
| Q3 24 | $237.1M | $158.1M | ||
| Q2 24 | $264.3M | $152.1M | ||
| Q1 24 | $266.7M | $147.3M |
总资产APLSSPT
| Q4 25 | $1.1B | $523.1M | ||
| Q3 25 | $1.1B | $481.4M | ||
| Q2 25 | $821.4M | $422.9M | ||
| Q1 25 | $807.3M | $424.7M | ||
| Q4 24 | $885.1M | $428.3M | ||
| Q3 24 | $901.9M | $388.8M | ||
| Q2 24 | $904.5M | $393.6M | ||
| Q1 24 | $831.9M | $389.9M |
负债/权益比APLSSPT
| Q4 25 | — | 0.20× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.15× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $10.9M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $9.9M |
| 自由现金流率自由现金流/营收 | -7.1% | 8.2% |
| 资本支出强度资本支出/营收 | 0.1% | 0.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $39.3M |
8季度趋势，按日历期对齐
经营现金流APLSSPT
| Q4 25 | $-14.2M | $10.9M | ||
| Q3 25 | $108.5M | $9.3M | ||
| Q2 25 | $4.4M | $5.1M | ||
| Q1 25 | $-53.4M | $18.1M | ||
| Q4 24 | $19.4M | $4.1M | ||
| Q3 24 | $34.1M | $9.0M | ||
| Q2 24 | $-8.3M | $2.1M | ||
| Q1 24 | $-133.0M | $11.2M |
自由现金流APLSSPT
| Q4 25 | $-14.3M | $9.9M | ||
| Q3 25 | $108.3M | $8.5M | ||
| Q2 25 | $4.4M | $4.2M | ||
| Q1 25 | $-53.4M | $16.7M | ||
| Q4 24 | $19.3M | $3.3M | ||
| Q3 24 | — | $8.5M | ||
| Q2 24 | $-8.4M | $1.6M | ||
| Q1 24 | $-133.3M | $10.1M |
自由现金流率APLSSPT
| Q4 25 | -7.1% | 8.2% | ||
| Q3 25 | 23.6% | 7.4% | ||
| Q2 25 | 2.5% | 3.7% | ||
| Q1 25 | -32.0% | 15.3% | ||
| Q4 24 | 9.1% | 3.0% | ||
| Q3 24 | — | 8.3% | ||
| Q2 24 | -4.2% | 1.6% | ||
| Q1 24 | -77.3% | 10.4% |
资本支出强度APLSSPT
| Q4 25 | 0.1% | 0.9% | ||
| Q3 25 | 0.0% | 0.7% | ||
| Q2 25 | 0.0% | 0.8% | ||
| Q1 25 | 0.0% | 1.2% | ||
| Q4 24 | 0.0% | 0.8% | ||
| Q3 24 | 0.0% | 0.5% | ||
| Q2 24 | 0.0% | 0.5% | ||
| Q1 24 | 0.2% | 1.1% |
现金转化率APLSSPT
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
SPT
暂无分部数据
